May 13, 2024
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis,...
May 13, 2024
Phil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis,...
Jun 30, 2023
Simon Allen is the CEO and Director of Anebulo Pharmaceuticals, which focuses on finding an effective treatment for acute cannabinoid intoxication or ACI, particularly in an emergency department setting. ACI is a condition where an individual has consumed or smoked too much cannabis or products that contain THC or...
Jun 30, 2023
Simon Allen is the CEO and Director of Anebulo Pharmaceuticals, which focuses on finding an effective treatment for acute cannabinoid intoxication or ACI, particularly in an emergency department setting. ACI is a condition where an individual has consumed or smoked too much cannabis or products that contain THC or...
Oct 3, 2022
Dr. Stacia Woodcock is Clinical Cannabis Pharmacist at Curaleaf, which is bringing medical and adult use of cannabis to several states throughout the country. Their model is to include a pharmacist in their dispensaries to educate practitioners and patients on the ways to use and manage cannabis products to address...